Instil Bio, Inc. · NASDAQ:TIL
Instil Bio — Investor Presentation (May 2025)
18 slides from Instil Bio's investor presentation, May 22, 2025
Slide 1: Instil Bio Corporate Presentation May 2025
Instil Bio Corporate Presentation May 2025 Nasdaq: TIL | www.instilbio.com EX-99.1
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” "expected,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “w
Slide 3: AXN-2510: PD-L1xVEGF Bispecific Antibody
3 Differentiated design • PD-L1 targeting • VEGF “trap” • ADCC-enhanced • PD-L1 inhibitor • VEGF blockade • PD-(L)1xVEGF bispecific antibody Validated oncology mechanisms • ~$50B in total 2024 sales for PD-(L)1 inhibitors for all indications Significant addressable market Collaboration with ImmuneOn
Slide 4: AXN-2510 Targets Largest Market in Oncology: NSCLC
AXN-2510 Targets Largest Market in Oncology: NSCLC 4 • NSCLC is the largest market opportunity for Keytruda, accounting for ~ 1/3 of sales • PD-(L)1 inhibitors are estimated to reach ~$90B in global sales in 20281 ▪ Four PD-(L)1 inhibitors achieved >$4B in sales in 20242 • VEGF inhibitor market repr
Slide 5: PD-(L)1xVEGF Bispecifics Outperform Pembrolizumab
PD-(L)1xVEGF Bispecifics Outperform Pembrolizumab 5 Time (months) P F S Ivonescimab: HARMONi-2 Trial1 BNT327 drove clinical benefit irrespective of PD-L1 status in combination with chemotherapy in patients with TNBC, demonstrating that PD-(L)1xVEGF bispecifics can potentially treat patient populatio
Slide 6: Leading PD-(L)1xVEGF Bispecific Antibodies
Designed to induce direct killing of immune- suppressive PD-L1+ tumor cells Designed for targeting the tumor microenvironment 6 Leading PD-(L)1xVEGF Bispecific Antibodies Anti-PD-L1 VHH Silenced Fc (LALA) Anti-PD-1 Anti-PD-L1 VEGF “Trap” ADCC- enhanced AXN-2510 (ImmuneOnco / Instil Bio) BNT327 (BioN
Slide 7: '2510 Demonstrates Robust Blockade of PD-1/PD-L1 Signaling
0.001 0.1 10 1000 0 1000 2000 3000 4000 Binding to CHO-PD1 Conc. (nM) M F I Ivonescimab Ivonescimab+VEGF165 hIgG1 IC50 Ivonescimab 5.464 Ivonescimab+VEGF165 2.094 0.001 0.1 10 1000 0 500 1000 1500 2000 Binding to CHO-PDL1 Conc. (nM) M F I IMM2510 IMM2510+VEGF165 hIgG1 IC50 IMM2510 2.035 IMM2510+VEGF
Slide 8: '2510 Development Strategy Prioritizes 1L NSCLC
‘2510 Development Strategy Prioritizes 1L NSCLC 8 2025 20262024 Phase 1b/2 Monotherapy Trial^ Ph2 1L NSCLC Chemotherapy Combo *As of Dec 24, 2024 data cut | **Subject to regulatory discussions ^Expected to be initiated before the end of 2025, assuming the necessary regulatory approvals are obtained.
Slide 9: Phase 1b/2 trial of '2510 + chemo in 1L NSCLC (China)
Phase 1b/2 trial of ‘2510 + chemo in 1L NSCLC (China)
Slide 10: Safety Update: Phase 1b/2 trial of '2510 + chemo in 1L NSCLC
Safety Update*** Phase 1b/2 trial of ‘2510 + chemo in 1L NSCLC (China) 10 2L+ Safety Run-in* 2510 10 mg/kg + chemo 1L NSCLC 2510 20 mg/kg + chemo 2510 20 mg/kg + chemo 2510 10 mg/kg + chemo *Safety run-in patients are patients with relapsed/refractory NSCLC **As of May 21, 2025 | ***As of May 9, 202
Slide 11: Phase 1/2 trial of '2510 monotherapy
Phase 1/2 trial of ‘2510 monotherapy
Slide 12: '2510 Phase 1/2 Monotherapy Trial Baseline Characteristics
12 ‘2510 Phase 1/2 Monotherapy Trial Baseline Characteristics Baseline characteristics Dose escalation; n=51 Dose expansion; n=55 Age: median (min – max) 58 (36 – 75) 47 (22 – 49) Race Asian 100% Asian 100% Gender: M / F (%) 43% / 57% 46% / 55% ECOG 0/1 (%) 8% / 92% 9% / 91% # of prior lines of ther
Slide 13: Efficacy Evaluable NSCLC Patients
13 13 Efficacy Evaluable NSCLC Patients Late-line, heavily pretreated patients (squamous and non-squamous) Sq: Squamous NSq: Non squamous NSq NSqNSq NSq NSq Sq Sq SqNSq NSq NSq NSq NSq TPS: NA TPS: NA TPS: <1% TPS: NA TPS: 40% TPS: 85% TPS: 1% TPS: 25% TPS: >50% TPS: NA TPS: <1% TPS: 5% TPS: NA Prio
Slide 14: Comparison of Phase 1/2 NSCLC Monotherapy Activity
Comparison of Phase 1/2 NSCLC Monotherapy Activity 14 EGFRm NSCLC who failed prior TKI EGFR/ALK wt who failed PD-1/L1 and platinum-based chemo BNT327 NSCLC 2L+ monotherapy (ASCO 2024) AXN-2510 NSCLC 2L+ monotherapy Source: Wu et al, ASCO 2024; Not from head-to-head trials. Differences in populations
Slide 15: Efficacy Evaluable NSCLC Pts Treated with Monotherapy '2510
15 13 Efficacy Evaluable NSCLC Pts Treated with Monotherapy ‘2510 Several patients with prolonged benefit Data cut-off date Dec 24, 2024; studies ongoing, data subject to change Data provided by ImmuneOnco (clinical trial sponsor)
Slide 16: '2510 Compares Favorably to Competitor Monotherapy Phase Datasets in NSCLC
‘2510 Compares Favorably to Competitor Monotherapy Phase 1 Datasets in NSCLC ‘25101 Ivonescimab2 BNT3273 BNT3273 Population All-comers EGFR/ALK/ROS wild-type EGFR mutant EGFR/ALK wild-type Indication NSCLC NSCLC NSCLC NSCLC Dose 3-20 mg/kg Q2W 10-30 mg/kg Q2/3W 20 mg/kg Q2W 20 mg/kg Q2W n (eff. eval
Slide 17: '2510 Safety Profile Comparison
‘2510 Safety Profile Comparison 17 Category Ivonescimab Phase 1a (n=51)1 BNT327 Phase 1a (n=80) 2 ‘2510 Phase 13 (n=106) TRAEs 74.5% 77.5% 94.3% TRAEs grade 3 27.5% 22.5% 21.7% Serious TRAEs 5.9% N/R 12.3% TRAEs leading to discontinuation 7.8% 10% 4.7% TRAEs leading to death 0% N/R 0.9%* Infusion-re
Slide 18: '2510 IRRs Are Generally Limited to 1st Infusion
‘2510 IRRs Are Generally Limited to 1st Infusion 18 0% 10% 20% 30% 40% 50% 60% 1st infusion 2nd infusion 3rd+ infusion IR R s p e r in fu s io n ‘2510: IRRs are infrequent after 1st infusion1 [1] ImmuneOnco internal data on file, n=106. Data cut off date Dec 24, 2024. Study is ongoing, data subject